Evidence map›Paper›PMID 30822619›Full record

ArticlePharmacological reports : PR2019

Effects of the human SULT1A1 polymorphisms on the sulfation of acetaminophen,O-desmethylnaproxen, and tapentadol.

Mohammed I Rasool, Ahsan F Bairam, Saud A Gohal, Amal A El Daibani, Fatemah A Alherz, Maryam S Abunnaja, Eid S Alatwi, Katsuhisa Kurogi, Ming-Cheh Liu

Open access · greenAbstract read
In one paragraph

Article in Pharmacological reports : PR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.6field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. The potential of curcumin in mitigating acetaminophen-induced liver damage.Naunyn-Schmiedeberg's archives of pharmacology · 2025
    Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 3 countries.

Mohammed I RasoolDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA; Department of Pharmacology, College of Pharmacy, University of Karbala, Karbala, Iraq.
Ahsan F BairamDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA; Department of Pharmacology, College of Pharmacy, University of Kufa, Najaf, Iraq.
Saud A GohalDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA.
Amal A El DaibaniDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA.
Fatemah A AlherzDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA.
Maryam S AbunnajaDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA.
Eid S AlatwiDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA.
Katsuhisa KurogiDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA; Biochemistry and Applied Biosciences, University of Miyazaki, Miyazaki 889-2192, Japan.
Ming-Cheh LiuDepartment of Pharmacology, College of Pharmacy and Pharmaceutical Sciences, University of Toledo Health Science Campus, Toledo, OH 43614, USA. Electronic address: ming.liu@utoledo.edu.
University of Toledo · USUniversity of Kerbala · IQUniversity of Kufa · IQUniversity of Miyazaki · JP

Funding

Ontogeny of the Phase II cytosolic sulfotransferases and adverse drug reactionsR03HD071146 · NICHD · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI LIU, MING-CHEH · 2012 to 2013
$146k
NICHD NIH HHS R03 HD071146
6 · The paper itself

Abstract

backgroundNon-opioid and opioid analgesics, as over-the-counter or prescribed medications, are widely used for the management of a diverse array of pathophysiological conditions. Previous studies have demonstrated the involvement of human cytosolic sulfotransferase (SULT) SULT1A1 in the sulfation of acetaminophen, O-desmethylnaproxen (O-DMN), and tapentadol. The current study was designed to investigate the impact of single nucleotide polymorphisms (SNPs) of the human SULT1A1 gene on the sulfation of these analgesic compounds by SULT1A1 allozymes.

methodsHuman SULT1A1 genotypes were identified by database search. cDNAs corresponding to nine SULT1A1 nonsynonymous missense coding SNPs (cSNPs) were generated by site-directed mutagenesis. Recombinant wild-type and SULT1A1 allozymes were bacterially expressed and affinity-purified. Purified SULT1A1 allozymes were analyzed for sulfation activity using an established assay procedure.

resultsCompared with the wild-type enzyme, SULT1A1 allozymes were shown to display differential sulfating activities toward three analgesic compounds, acetaminophen, O-desmethylnaproxen (O-DMN), and tapentadol, as well as the prototype substrate 4NP.

conclusionResults obtained indicated clearly the impact of genetic polymorphisms on the drug-sulfation activity of SULT1A1 allozymes. Such information may contribute to a better understanding about the differential metabolism of acetaminophen, O-DMN, and tapentadol in individuals with different SULT1A1 genotypes.

Indexed as

AcetaminophenAnalgesics, Non-NarcoticAnalgesics, OpioidArylsulfotransferaseCytosolEscherichia coliGenotypeHumansIsoenzymesMutagenesis, Site-DirectedNaproxenPolymorphism, Single NucleotideSulfatesTapentadolAcetaminophenAnalgesics, Non-NarcoticAnalgesics, OpioidArylsulfotransferasedesmethylnaproxenIsoenzymesNaproxenSulfatesSULT1A1 protein, humanTapentadolAcetaminophenO-desmethylnaproxenSingle nucleotide polymorphismsSULT1A1Tapentadol

Identifiers

PMID30822619
PMCPMC6498441
OpenAlexW2905108262

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.